Most prior efforts aimed at targeting CXCR3 for therapeutic benefit have focused on chronic autoimmune diseases such as multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis [5,18-20]. The gene discussed is CXCR3; the disease is inflammatory bowel disease.